The Use of Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinomas in a Basal Cell Nevus Syndrome Patient

Kagy, Matthew K.; Amonette, Rex A.

doi:10.1046/j.1524-4725.2000.00003.x

Cited by 107 publications

(87 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It usually occurs in regions of lower fur density and lesser pigmentation such as the nose, pinnae and periocular region (Rodaski and Werner, 2009). In mammals, the causes and pathogenetic mechanisms of the disease are very similar to others involved in actinic keratosis (Festa-Neto, 2002), a dysplasia of keratinocytes (Kagy and Amonette, 2000) that is usually a consequence of solar dermatitis (Festa-Neto, 2002;Grupta et al, 2002).…”

Section: Avaliaram-se a Viabilidade E A Eficácia Da Utilização Do Imimentioning

confidence: 88%

Topical treatment of actinic keratosis with imiquimod 5% cream

Garcez¹,

Gerardi

Ferreira

et al. 2012

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

The viability and the efficiency of imiquimod 5% cream in a cat which suffered from nasal actinic keratosis were evaluated. The procedures were carried out at home by the owners themselves. Six packets of the cream were used, one per week, in three consecutive daily applications, with a four-day interval (without treatment). The cytological results were negative for neoplastic cells 30 days after the end of the treatment. A clinical revision was conducted 18 months later and the animal showed no signs of recurrence. The cream proved to be safe and efficient. There are no reports regarding efficiency in animals concerning the treatment with imiquimod 5% cream and also regarding other effects related to this treatment. A case report presenting a positive response can reveal with terapeutical possibilities that it would be easily available and applicable for all professionals. In the future it would be a new alternative to avoid progressions of this kind of neoplasia which is often observed in the small animal clinic.

show abstract

Section: Avaliaram-se a Viabilidade E A Eficácia Da Utilização Do Imimentioning

confidence: 88%

Topical treatment of actinic keratosis with imiquimod 5% cream

Garcez¹,

Gerardi

Ferreira

et al. 2012

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

show abstract

“…It has also been used successfully to treat patients with intraepidermal neoplasia including Bowen’s disease [25, 26, 27, 28, 29, 30, 31]. Several studies and case reports on the use of imiquimod in the treatment of multiple BCC indicate its effectiveness, especially in patients with multiple or difficult-site disease [32, 33, 34]. However, histological clearance is only obtained in 65–90% of the patients.…”

Section: Discussionmentioning

confidence: 99%

Nudging Epidermal Field Cancerogenesis by Imiquimod

et al. 2003

View full text Add to dashboard Cite

Background: The coexistence of malignancies close to each other on the skin has been occasionally reported. The concept of field cancerogenesis applies to such cases. Given the purported mechanism of action of imiquimod, it should not be surprising that this treatment could inhibit epidermal field cancerogenesis. Aim: To assess the effect of imiquimod applied twice weekly on incipient bowenoid changes disclosed in the vicinity of basal cell carcinomas. Materials and Method: Biopsies were taken before treatment and after 4–6 weeks and 12 weeks of imiquimod treatment. Results: Large atypical bowenoid keratinocytes and dyskeratotic cells were cleared in time while factor-XIIIa-positive dermal dendrocytes appeared boosted and admixed with a brisk lymphocytic infiltration. Conclusion: Epidermal field cancerogenesis appears to be controlled by imiquimod. Dermal dendrocytes might play a pivotal role in this regression phenomenon.

show abstract

“…Finally, some case reports (no RCTs) have claimed positive responses to topical IQ 5% in large superfi cial BCCs (Shumack et al 2004;Micali et al 2005) and multiple BCCs as observed in Gorlin syndrome (Kagy and Amonette 2000;Micali, Lacarrubba, et al 2003).…”

Section: Basal Cell Carcinomamentioning

confidence: 99%

Advances in the use of topical imiquimod to treat dermatologic disorders

Micali¹

2008

TCRM

View full text Add to dashboard Cite

Imiquimod (IQ) is an immune-response modifying agent, fi rst approved by FDA for the topical treatment of external genital and perianal warts in 1997. It induces, through stimulation of Toll-like receptors (TLRs) localized on the surface of antigen-presenting cells, synthesis and release of several endogenous pro-infl ammatory cytokines such as interferon-α (IFN-α), tumor necrosis factor-α (TNF-α) and interleukins (IL) 6 and 12, which in turn stimulate both the innate and acquired immune pathways, resulting in upregulation of natural antiviral and antitumor activity. IQ 5% cream has been used for the treatment of a wide variety of dermatologic conditions in which the immune system is thought to play a role in regression of the disease. In some disorders, such as genital and perianal warts, actinic keratoses, basal cell carcinomas, Bowen's disease and molluscum contagiosum, relative safety and effi cacy are supported by randomized controlled trials of IQ. However, it is common for patients to experience local skin reactions, which can range from mild to severe in intensity, but usually resolve 1-2 weeks after interrupting treatment. Additional randomized trials are encouraged to assess safety and effi cacy of IQ in the treatment of an even wider range of cutaneous disorders.

show abstract

The Use of Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinomas in a Basal Cell Nevus Syndrome Patient

Abstract: Imiquimod 5% cream appears to be effective in eradicating superficial nonfacial BCCs. The degree of local inflammatory response may affect the patients' tolerability of treatment and therefore patient compliance.

Cited by 107 publications

References 4 publications

Topical treatment of actinic keratosis with imiquimod 5% cream

Topical treatment of actinic keratosis with imiquimod 5% cream

Nudging Epidermal Field Cancerogenesis by Imiquimod

Advances in the use of topical imiquimod to treat dermatologic disorders

Contact Info

Product

Resources

About